Anti-CD47 monoclonal antibody (magrolimab biosimilar)

Home/ Products / Biosimilar Antibodies

PRODUCT

  • SKU

    DMA1001-100uL

  • Size

    100uL

  • Price

    $320

1
Magrolimab is a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome (MDS). It is in Phase III clinical trial. The antibody was delveloped by Gilead.
target CD47
gene id 961
alias CD47, MER6, IAP
reactivity Human
host Human
clonality Monoclonal
clone number Hu5F9-G4
iso type IgG4
formulation Purified from cell culture supernatant by affinity chromatography; Kept in PBS (pH 7.4) with 0.1% BSA, 0.1% ProClin 300 and 50% Glycerol
applications ELISA, Flow Cytometry
dilution ELISA 1:5000-10000
shipping With ice packs
storage Store at -20°C for at least 1 year. Avoid multiple freeze-thaw cycles.

PRODUCT

  • SKU

    DMA1001-100uL

  • Size

    100uL

  • Price

    $320

1